/
Other
Fibrosis
154
Pipeline Programs↗
223
Active Trials↗
132
Companies Involved↗
Fibrosis is a highly competitive landscape with 154 programs across 132 companies. The most active players are Endeavor Biomedicines, Inc., Hepion Pharmaceuticals, Inc.. 26 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical72
Phase 111
Phase 245
Phase 326
Approved
No programs
Analysis
Modality Breakdown
94%
Small molecule
121 of 129 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 129 classified programs, each share of the total. Modality classified for 94% of 154 pipeline programs.
Analysis
Trial Status
1,056
clinical trials
Completed602 · 57%
Recruiting123 · 12%
Terminated105 · 10%
Unknown status78 · 7%
Active, not recruiting49 · 5%
Not yet recruiting44 · 4%
Other55 · 5%
Clinical Trials
Trial Activity
1056 trials
Natural History of Noncirrhotic Portal Hypertension
Recruiting·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·N/A·NCT02417740·400 enrolled
Page 1 of 71
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)